摘要
用酶联法、同位素掺入法、同位素释放法等检测肿瘤病人血清可溶性白介素2受体(sIL-2R)、肿瘤坏死因子(TNF)、自然杀伤(NK)细胞活性、LAK细胞活性、淋巴细胞转化及淋巴细胞对白细胞介素2(IL-2)的反应性等免疫功能.结果表明:肿瘤病人血清sIL-2R(241.9±172.5pmol/L)、TNF(1.86±1.52ng/ml)含量均显著高于健康对照组(分别为:0.63±0.20ng/ml,134.2±76.5pmol/L,P<0.05～0.005).而肿瘤病人NK细胞活性(11.18±6.98)、LAK细胞活性(17.86±9.57)、淋巴细胞转化(32.83±52.59)、淋巴细胞对IL-2的反应性(5.91±9.31)等均显著低于健康对照组(分别为:20.33±10.97,38.49±8.10,75.70±52.65和24.59±28.25,P<0.04～0,001).结果提示:肿瘤病人存在着多种免疫功能的改变,故应给予合理的过继免疫治疗.
Immue functions of patients with advanced carcinoma were assayed in our lab. The re-sults showed that in patients with cancer, lyrnphocyte transformation was 32. 83 ±52. 59, responses oflymphocytes to IL-25. 94± 9. 31,to IL-2/PHA 32.25 ±43.05 In the healthy control,they were 75. 70±52. 65, 24. 59 ± 28. 25, 125. 47 ± 74. 11 respectively, P< 0.001. NK activity 11.18 ± 6. 98 LAK activity17. 86± 9. 57 , sIL-2R and TNF (concentrations 241. 9 ± 172. 5 pmol/L and 1. 86 ±1. 52 ng/ml respec-tively) in patients with cancer were significantly higher than those in healthy controls (134. 2 ± 73. 5pmol/L and 0. 63 ±0. 20 ng/ml respectively, P<0.05 and 0.001 ). It was concluded that the re-sponses of lymphocytes to IL-2, NK activity and LAK activity in patients with cancer were suppressed.It showed that LAK cells from patients with cancer might not be able to play an antitumor role and wasnot as effective as those from healthy donor.
